[MO36] Mini-Oral Session 36　Palliative Care / Symptom Management 2

[MO36-3] Multicenter survey analyzing the use of olanzapine for breakthrough chemotherapy-induced nausea and vomiting

^○Koki Hashimoto¹, Toshinobu Hayashi², Mototsugu Shimokawa³, Reiko Matsui⁴, Maki Todo⁵, Shinya Tamaki⁶, Tomohiko Harada⁷, Motohiko Sano⁸, Yasumasa Koike⁹, Yukiyoshi Fujita¹⁰, Hirotoshi Iihara¹¹, Hironobu Hashimoto¹², Hiroko Minatogawa¹³, Masayo Komoda¹⁴, Masakazu Abe¹⁵, Naoki Inui¹⁶, Kenji Okita¹⁷, Junichi Nishimura¹⁸, Nobuyuki Yamamoto¹⁹, Mitsue Saito²⁰ (1.Department of Pharmacy, Japanese Foundation for Cancer Research, Cancer Institute Hospital, 2.Faculty of Pharmaceutical Sciences, Fukuoka University, 3.Department of Biostatistics, Yamaguchi University, 4.Department of Pharmacy, National Cancer Center Hospital East, 5.Department of Pharmacy, Saitama Medical University International Medical Center, 6.Department of Pharmacy, KKR Sapporo Medical Center, 7.Department of Pharmacy, Kanagawa Cancer Center, 8.Division of Applied Pharmaceutical Education and Research, Hoshi University, 9.Department of Pharmacy, National Hospital Organization Shikoku Cancer Center, 10.Division of Pharmacy, Gunma Prefectural Cancer Center, 11.Department of Pharmacy, Gifu University Hospital, 12.Department of Pharmacy, National Cancer Center Hospital, 13.Department of Pharmacy, St. Marianna University School of Medicine Hospital, 14.Department of Pharmacy, Chiba-Nishi General Hospital, 15.Department of obstetrics and gynecology, Hamamatsu University School of Medicine, 16.Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, 17.Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, 18.Department of Gastroenterological Surgery, Osaka International Cancer Institute, 19.Internal Medicine III, Wakayama Medical University, 20.Department of Breast Oncology, Juntendo University Hospital)